



Bal Pharma Limited

25.9.2020

To,
The Manager-Listing
BSE Limited
Mumbai.

To
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub: Proceedings of 33rd Annual General Meeting ('AGM') held on 25.9.2020.
Ref : Scrip code 524824 for BSE and BALPHARMA for NSE.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the 33rd Annual General Meeting of the Company conducted through audio visual means on 25.09.2020.

The Meeting commenced at 11.00 AM and concluded at 11.50 AM.

Ordinary Business:

1. Approved the Audited standalone and consolidated financial statements of the Company for the financial year ended 31.3.2020, together with Board's report and Independent Auditors Report.
2. Reappointed Mr. Shailesh Siroya, who is retiring by rotation and being eligible offered himself for reappointment.

Special Business:

3. Approved the appointment of Mr. Himesh Virupakshaya (DIN # 08554422) as a Director of the Company.
4. Approved the appointment of Mr. Himesh Virupakshaya as whole time Director of the Company.
5. Approved the appointment of Mr. H.S Venkatesh (DIN # 01776040) as Independent Director of the Company.

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 41570813 / 19 Fax : 41570820



6. Approved the appointment of Ms.Nicola Neeladri (DIN # 01997936) as Independent Director of the Company .
7. Authorised the Board of Directors to exercise powers pursuant to Section 180(1)(a) of the Companies Act,2013.
8. Approved renewal of contract with Desa Marketing International.
9. Approved the issue of 14,00,000 warrants to Mr.Shailesh Siroya, promoter of the Company , on preferential basis .
10. Ratified the remuneration payable to the Cost Auditors.

Kindly note that e-voting results will be announced after receipt of Scrutinizer's Report and the same will be submitted to the exchanges as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and also uploaded on our website.

Please take this intimation on record.

Thanking you

For Bal Pharma Limited


Shailesh Siroya
Managing Director.

